Sugi Predict

Sugi Predict / Compounds / SCHEMBL554576

SCHEMBL554576

SCHEMBL554576

CCOC(=O)c1nnc(Cc2ccccc2)o1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.52
▸ SMN1; SMN2 Q16637 5/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ MAPT P10636 3/20 0.49
▸ KLKB1 P03952 1/20 0.47
▸ HPGD P15428 3/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ LMNA P02545 1/20 0.46
▸ TSHR P16473 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ GPR55 Q9Y2T6 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7154321 0.87 POLB (0.49) SMN1; SMN2ALDH1A1MAPTHPGDNPC1
SCHEMBL19805436 0.87 NPSR1 (0.56) NPSR1SMN1; SMN2ALDH1A1MAPTKLKB1
SCHEMBL756599 0.86 NPSR1 (0.70) NPSR1SMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL26703571 0.86 MAPK1 (0.59) NPSR1SMN1; SMN2ALDH1A1MAPTNPC1
SCHEMBL20050243 0.86 NPSR1 (0.53) NPSR1SMN1; SMN2ALDH1A1LMNATSHR
SCHEMBL26703814 0.81 POLB (0.51) NPSR1SMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL19228547 0.80 TSHR (0.52) SMN1; SMN2ALDH1A1MAPTKLKB1HPGD
SCHEMBL28987843 0.80 SMN1; SMN2 (0.67) NPSR1SMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL553755 0.80 RAB9A (0.54) NPSR1SMN1; SMN2ALDH1A1MAPTKLKB1
SCHEMBL29012435 0.79 RAB9A (0.53) NPSR1SMN1; SMN2ALDH1A1MAPTKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630554-B2 Pyrimidinone compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED (CN) 2026-05-19 — — US disclosed
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 — — US disclosed
EP-4055021-B1 HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS RIGEL PHARMACEUTICALS INC (US) 2025-10-08 — — EP disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 — — US disclosed
US-20250092057-A1 HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS RIGEL PHARMACEUTICALS, INC. 2025-03-20 — — US disclosed
CN-115298184-B Heterocyclic RIP1 inhibiting compounds 里格尔药品股份有限公司 2025-01-28 — — CN disclosed
CN-118994190-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-118994191-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-114437105-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-10-11 — — CN disclosed
US-20240150376-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2024-05-09 — — US disclosed
US-9290485-B2 N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides NOVARTIS AG (CH) 2016-03-22 — — US disclosed
US-9290485-B2 N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides NOVARTIS AG (CH) 2016-03-22 — — US disclosed
US-9290485-B2 N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides NOVARTIS AG (CH) 2016-03-22 — — US disclosed
EP-2601189-B1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN NOVARTIS AG (CH) 2015-04-15 — — EP disclosed
EP-2601189-B1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN NOVARTIS AG (CH) 2015-04-15 — — EP disclosed
EP-2601189-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN Novartis AG (CH) 2013-06-12 — — EP disclosed
US-20120035168-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES NOVARTIS AG (CH) 2012-02-09 — — US disclosed
US-20120035168-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES NOVARTIS AG (CH) 2012-02-09 — — US disclosed
US-20120035168-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES NOVARTIS AG (CH) 2012-02-09 — — US disclosed
WO-2012017020-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN NOVARTIS AG (CH) 2012-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 NPSR1 2688/4885SMN1; SMN2 2572/4885ALDH1A1 3854/4885
US-20240150376-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB NPSR1 4297/4885SMN1; SMN2 2486/4885ALDH1A1 4405/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB NPSR1 4297/4885SMN1; SMN2 2486/4885ALDH1A1 4405/4885
US-20250092057-A1 HETEROCYCLIC RIP1 INHIBITORY COMPOUNDS RIPK1, RIPK2, RIPK3 NPSR1 4446/4885SMN1; SMN2 2209/4885ALDH1A1 4391/4885
US-20120035168-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES TPMT, REN, PNMT NPSR1 269/4885SMN1; SMN2 2231/4885ALDH1A1 1337/4885
US-12630554-B2 Pyrimidinone compounds and uses thereof CYP2D6, TPMT, CYP2B6 NPSR1 461/4885SMN1; SMN2 1364/4885ALDH1A1 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.